Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM

Neuro-Oncology

Volumn 12, Issue 11, 2010, Pages 1152-1161

  Srinivasan, Radhika ^a   Phillips, Joanna J ^a   Berg, Scott R Vanden ^c   Polley, Mei Yin C ^b   Bourne, Gabriela ^a   Au, Alvin ^b   Pirzkall, Andrea ^a   Cha, Soonmee ^a   Chang, Susan M ^b   Nelson, Sarah J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

GBM; MR spectroscopy; Myo inositol; Treatment effect

Indexed keywords

ARTICLE; ASTROCYTOSIS; CANCER GROWTH; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL ASSESSMENT; EX VIVO STUDY; GLIOBLASTOMA; HUMAN; IN VIVO STUDY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TUMOR VOLUME;

BRAIN NEOPLASMS; CHOLINE; GLIOBLASTOMA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; NEURONAVIGATION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 78650102881     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq075     Document Type: Article

References (36)

1. Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. Lancet Oncol. 2005;6:167-175.
2. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
3. Rees JH, Smirniotopoulos JG, Jones RV, Wong K. Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics. 1996;16: 1413-1438. quiz 1462-1413.
4. Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S. Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol. 2006;37:272-282.
5. Cheng LL, Chang IW, Louis DN, Gonzalez RG. Correlation of highresolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res. 1998;58:1825-1832.
6. Righi V, Roda JM, Paz J, Mucci A, Tugnoli V, Rodriguez-Tarduchy G, et al. 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. NMR Biomed. 2009;22:629-637.
7. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA. 1997;94:6408-6413.
8. Tkac I, Oz G, Adriany G, Ugurbil K, Gruetter R. In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med. 2009;62: 868-879.
9. Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, et al. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J Neurooncol. 2009;91:337-351.
10. Ziarelli F, Caldarelli S. Solid-state NMR as an analytical tool: quantitative aspects. Solid State Nucl Magn Reson. 2006;29:214-218.
11. Ratiney H, Sdika M, Coenradie Y, Cavassila S, van Ormondt D, Graveron-Demilly D. Time-domain semi-parametric estimation based on a metabolite basis set. NMR Biomed. 2005;18:1-13.
12. Chen AP, Cunningham CH, Ozturk-Isik E, Xu D, Hurd RE, Kelley DA, et al. High-speed 3T MR spectroscopic imaging of prostate with flyback echoplanar encoding. J Magn Reson Imaging. 2007;25:1288-1292.
13. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors. Magn Reson Med. 2001;46:228-239.
14. Khayal IS, Crawford FW, Saraswathy S, Lamborn KR, Chang SM, Cha S, et al. Relationship between choline and apparent diffusion coefficient in patients with gliomas. J Magn Reson Imaging. 2008;27:718-725.
15. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B. 1996;111:209-219.
16. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci. 1993;15:289-298.
17. McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW, et al. Histopathological validation of a threedimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg. 2002;97:794-802.
18. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252:182-189.
19. Gupta RK, Cloughesy TF, Sinha U, Garakian J, Lazareff J, Rubino G, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol. 2000;50:215-226.
20. Senft C, Hattingen E, Pilatus U, Franz K, Schanzer A, Lanfermann H, et al. Diagnostic value of protonmagnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values. Neurosurgery. 2009;65:908-913. discussion 913.
21. Thurston JH, Sherman WR, Hauhart RE, Kloepper RF. Myo-inositol: a newly identified nonnitrogenous osmoregulatory molecule in mammalian brain. Pediatr Res. 1989;26:482-485.
22. Strange K, Emma F, Paredes A, Morrison R. Osmoregulatory changes in myo-inositol content and Na+/myo-inositol cotransport in rat cortical astrocytes. Glia. 1994;12:35-43.
23. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, et al. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology. 2008;248:210-220.
24. Fernando KT, McLean MA, Chard DT, MacManus DG, Dalton CM, Miszkiel KA, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2004;127: 1361-1369.
25. Hattingen E, Raab P, Franz K, Zanella FE, Lanfermann H, Pilatus U. Myo-inositol: a marker of reactive astrogliosis in glial tumors? NMR Biomed. 2008;21:233-241.
26. Castillo M, Smith JK, Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol. 2000;21:1645-1649.
27. Kinoshita Y, Yokota A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed. 1997;10:2-12.
28. Lehnhardt FG, Bock C, Rohn G, Ernestus RI, Hoehn M. Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed. 2005;18: 371-382.
29. Righi V, Andronesi OC, Mintzopoulos D, Black PM, Tzika AA. High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. Int J Oncol. 36:301-306.
30. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, et al. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res. 2009;69:7548-7556.
31. Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs. 2001;4:419-426.
32. Sabatier J, Gilard V, Malet-Martino M, Ranjeva JP, Terral C, Breil S, et al. Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. Invest Radiol. 1999;34:230-235.
33. Bell JD, Bhakoo KK. Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. NMR Biomed. 1998;11: 354-359.
34. Londono A, Castillo M, Armao D, Kwock L, Suzuki K. Unusual MR spectroscopic imaging pattern of an astrocytoma: lack of elevated choline and high myo-inositol and glycine levels. AJNR Am J Neuroradiol. 2003;24:942-945.
35. van den Bent MJ, Vogelbaum MA,Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009;27:2905-2908.
36. Srinivasan R, Vigneron D, Sailasuta N, Hurd R, Nelson S. A comparative study of myo-inositol quantification using LCmodel at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain. Magn Reson Imaging. 2004;22:523-528.